Ponatinib Induced Stroke
暂无分享，去创建一个
[1] A. Russo,et al. Management of Ponatinib in Patients with Chronic Myeloid Leukemia with Cardiovascular Risk Factors , 2019, Chemotherapy.
[2] T. Force,et al. Ponatinib-induced cardiotoxicity: delineating the signalling mechanisms and potential rescue strategies , 2019, Cardiovascular research.
[3] D. Schadendorf,et al. Cardiovascular diseases in patients receiving small molecules with anti-vascular endothelial growth factor activity: A meta-analysis of approximately 29,000 cancer patients , 2018, European journal of preventive cardiology.
[4] M. Breccia,et al. Ponatinib: A Review of Efficacy and Safety. , 2017, Current cancer drug targets.
[5] U. Olsson‐Strömberg,et al. Cardiovascular Events Associated With Use of Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia: A Population-Based Cohort Study. , 2016, Annals of internal medicine.
[6] T. Clackson,et al. A phase 2 trial of ponatinib in Philadelphia chromosome-positive leukemias. , 2013, The New England journal of medicine.
[7] C. Gambacorti-Passerini,et al. Choosing the right TKI for chronic myeloid leukemia: When the truth lies in “long‐term” safety and efficacy , 2011, American journal of hematology.